+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05713006

Study of Alectinib Dose Escalation to Evaluate Pharmacokinetics and Effectiveness in Adults with ALK-Positive Advanced Non-small Cell Lung Cancer

Led by Instituto Nacional de Cancerologia de Mexico · Updated on 2026-04-08

45

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the pharmacokinetics of alectinib, an oral drug given to Mexican patients with advanced ALK-positive non-small cell lung cancer NSCLC. The study aims to find out the peak blood concentrations of alectinib as the dose increases from 300 mg to 600 mg twice daily over nine weeks. It also evaluates how well patients respond to the treatment and tracks disease progression and side effects over time. In the first phase, patients take alectinib in increasing doses every 21 days, starting at 300 mg twice daily and moving up in 150 mg steps to 600 mg twice daily. Blood samples are collected before and after doses on specific days to measure drug levels. After this phase, patients continue treatment with the dose chosen based on earlier results until their disease worsens or side effects become unacceptable. This phase also measures the overall response rate to the drug. Participants will have regular assessments including blood tests, imaging scans every six weeks to monitor tumor response, and evaluations of side effects and survival. Researchers will measure drug concentration levels, treatment response, progression-free survival, and overall survival throughout the study. The study lasts several months, with close observation during dose escalation and ongoing follow-up during treatment.

CONDITIONS

Brief Title

Alectinib Pharmacokinetic in Patients With NSCLC

Research Team

O

Oscar G Arrieta Rodriguez, M.D., M.Sc.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here